Trial Profile
A Multicenter registry to evaluate the safety and efficacy of Stentys Drug-Eluting Stent (Sirolimus) in Left Main Coronary Artery Percutaneous intervention : LM-STENTYS Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2018
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- 31 Oct 2018 New trial record
- 25 Sep 2018 Results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics